A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

This trial tests F8IL10, a new drug that delivers an anti-inflammatory protein (interleukin-10) directly into inflamed joints, as a treatment for rheumatoid arthritis. Rather than suppressing the entire immune system, this targeted approach aims to reduce joint inflammation locally with fewer whole-body side effects. **You may be eligible if...** - You are 18 to 80 years old - You have a confirmed rheumatoid arthritis (RA) diagnosis for more than 6 months - You have active joint flare(s) in a knee, ankle, shoulder, wrist, or elbow that are suitable for an injection, despite your current treatment - You are on stable RA medication **You may NOT be eligible if...** - You have active joint infection or recent joint surgery - You have certain serious infections (HIV, hepatitis, active tuberculosis) - You are pregnant or breastfeeding - You have significant liver, kidney, or blood disorders Talk to your doctor to see if this trial is right for you.